Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2025 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
April 04, 2025 16:05 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
April 02, 2025 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
March 05, 2025 16:05 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
March 03, 2025 07:01 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

– $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – ...
February 25, 2025 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Participation in March Investor Conferences

WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
February 24, 2025 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
May 24, 2017 19:22 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Prices Public Offering of Common Stock

WALTHAM, Mass., May 24, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today the pricing of an underwritten public offering of 3,750,000 shares of its common stock at...
May 23, 2017 16:48 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., May 23, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today that it plans to offer and sell, subject to market and other conditions, $50 million of...
May 17, 2017 17:07 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma

-31% objective response rate for first stage of the Phase 2 melanoma cohort of ENCORE 601- -Enrollment ongoing in Stage 2, along with biomarker analysis- -ENCORE 601 now enrolling expanded cohorts...